Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

511 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO).
Barosi G, Boccadoro M, Cavo M, Corradini P, Marchetti M, Massaia M, Merlini G, Tosi P, Tura S; Italian Society of Hematology; Italian Society of Experimental Hematology; Italian Group for Bone Marrow Transplantation. Barosi G, et al. Among authors: boccadoro m. Haematologica. 2004 Jun;89(6):717-41. Haematologica. 2004. PMID: 15194540 Free article. Review.
Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma.
Corradini P, Cavo M, Lokhorst H, Martinelli G, Terragna C, Majolino I, Valagussa P, Boccadoro M, Samson D, Bacigalupo A, Russell N, Montefusco V, Voena C, Gahrton G; Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Corradini P, et al. Among authors: boccadoro m. Blood. 2003 Sep 1;102(5):1927-9. doi: 10.1182/blood-2003-01-0189. Epub 2003 May 8. Blood. 2003. PMID: 12738666 Free article. Clinical Trial.
New drugs for treatment of multiple myeloma.
Bruno B, Rotta M, Giaccone L, Massaia M, Bertola A, Palumbo A, Boccadoro M. Bruno B, et al. Among authors: boccadoro m. Lancet Oncol. 2004 Jul;5(7):430-42. doi: 10.1016/S1470-2045(04)01511-6. Lancet Oncol. 2004. PMID: 15231250 Review.
Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial.
Palumbo A, Bringhen S, Petrucci MT, Musto P, Rossini F, Nunzi M, Lauta VM, Bergonzi C, Barbui A, Caravita T, Capaldi A, Pregno P, Guglielmelli T, Grasso M, Callea V, Bertola A, Cavallo F, Falco P, Rus C, Massaia M, Mandelli F, Carella AM, Pogliani E, Liberati AM, Dammacco F, Ciccone G, Boccadoro M. Palumbo A, et al. Among authors: boccadoro m. Blood. 2004 Nov 15;104(10):3052-7. doi: 10.1182/blood-2004-02-0408. Epub 2004 Jul 20. Blood. 2004. PMID: 15265788 Free article. Clinical Trial.
Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma.
Palumbo A, Avonto I, Bruno B, Falcone A, Scalzulli PR, Ambrosini MT, Bringhen S, Gay F, Rus C, Cavallo F, Falco P, Massaia M, Musto P, Boccadoro M. Palumbo A, et al. Among authors: boccadoro m. Clin Lymphoma Myeloma. 2006 May;6(6):475-7. doi: 10.3816/CLM.2006.n.028. Clin Lymphoma Myeloma. 2006. PMID: 16796778 Clinical Trial.
511 results